ARIAD Pharmaceuticals, Inc. is a global oncology company engaged in the discovery, development and commercialization of medicines for the cancer patients. The Company’s products that include Iclusig (ponatinib), AP26113 and ridaforolimus, were discovered based on computational and structure-based drug design. Iclusig is known to demonstrate activity against the T315I gatekeeper mutation of BCR-ABL, the most common mutation occurring in approximately 10% of patients with drug resistance. AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin, or mTOR, that the Company discovered and developed internally.